Personality Disorders
Personality disorders, characterised by enduring patterns of behaviour, cognition, and inner experience, present substantial challenges in treatment. Emerging research into psychedelics such as psilocybin, MDMA, and ketamine indicates that they may offer novel therapeutic avenues for addressing these complex conditions.
Key Insights
- 1
Psychedelic-assisted therapy has demonstrated potential in improving emotional regulation and interpersonal relationships in patients with personality disorders.
- 2
Research indicates that compounds like psilocybin and MDMA may enhance therapeutic outcomes when combined with psychotherapy.
- 3
Recent studies suggest that psychedelics can induce neuroplasticity, which may facilitate lasting changes in personality and behaviour patterns.
- 4
Clinical trials show that psychedelic therapy can reduce symptoms of personality disorders, leading to greater overall well-being.
- 5
The integration of psychedelics in treatment protocols could significantly reduce healthcare costs associated with chronic mental health conditions.
What is Personality Disorders?
Personality disorders are a group of mental health conditions that involve deeply ingrained, inflexible patterns of thinking, feeling, and behaving, which deviate markedly from cultural expectations and lead to significant distress or impairment.
The symptoms of personality disorders vary widely but may include difficulties in interpersonal relationships, emotional instability, impulsive behaviours, and challenges in regulating emotions.
Pathophysiologically, personality disorders are believed to result from a complex interplay of genetic, environmental, and psychological factors, often beginning in adolescence or early adulthood.
Current Treatments
Standard treatments for personality disorders typically include psychotherapy (such as Dialectical Behaviour Therapy and Cognitive Behavioural Therapy) and pharmacotherapy, which may involve antidepressants, mood stabilisers, or antipsychotics. However, many patients remain resistant to conventional treatments.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Personality Disorders.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Multiple studies demonstrate significant therapeutic benefits and symptom reduction associated with psilocybin use in personality disorders. | Large | High | Consistent |
| MDMA Well-documented efficacy in therapeutic settings for emotional openness and interpersonal improvement. | Large | High | Consistent |
| Ketamine Effects can vary significantly based on individual response and treatment protocols. | Medium | Moderate | Inconsistent |
Psilocybin and Personality Disorders
Psilocybin has shown promise in altering self-referential thought patterns and increasing feelings of connectedness, which can be particularly beneficial for individuals with personality disorders. In clinical settings, psilocybin can facilitate transformative experiences leading to greater emotional insight and a decrease in maladaptive behaviours. This compound is also associated with neuroplastic changes that may help in reshaping interpersonal dynamics and emotional regulation over time.
MDMA and Personality Disorders
MDMA's unique empathogenic effects enable users to experience enhanced emotional openness and trust, making it particularly useful in psychotherapy for personality disorders. In therapeutic contexts, MDMA can lower defensiveness and hostility, which are common in these patients, allowing for deeper exploration of emotions and relationships. Studies indicate significant improvements in affect regulation and interpersonal connection following MDMA-assisted psychotherapy.
Clinical Outlook
The future of psychedelic treatment for personality disorders appears promising, with ongoing clinical trials enhancing our understanding of their efficacy and safety. As regulatory frameworks evolve, psychedelics may soon become an integral part of comprehensive treatment plans, offering hope to individuals who struggle with the limitations of traditional therapies.
Industrial Landscape
Key players in the psychedelic research landscape include the Multidisciplinary Association for Psychedelic Studies (MAPS), the Beckley Foundation, and various biotechnology companies conducting Phase 2 and Phase 3 trials on psychedelic interventions.
Quick Indicators
Related Topics
Organisations
Search →University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
University of Washington
At UW, researchers are working on clinical trials with psilocybin (provided by Usona). Dr Anthony Back, co-director of the University's Center for Excellence in Palliative Care, led a trial exploring the effects of psilocybin to alleviate the mental health burden inflicted on frontline healthcare workers throughout the COVID-19 pandemic. As Seattle became the largest city in the US to decriminalise psilocybin mushrooms in October 2021, and with ongoing legislative efforts at the state level, more research with psychedelics is anticipated and occurring at UW.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation (MRO) headquartered in Madison, Wisconsin. Co-founded in 2014 by Bill Linton (CEO of Promega Corporation) and Malynn Utzinger, M.D., Usona was established after Linton witnessed the profound impact of a Johns Hopkins psilocybin study on a terminally ill friend. Unlike commercial drug developers, Usona operates as a mission-driven MRO — conducting and supporting pre-clinical and clinical research on psilocybin and other consciousness-expanding medicines, with the goal of developing accessible, affordable treatments. Its research leadership includes Dr. Charles Raison (Director of Clinical and Translational Research, UW-Madison psychiatrist) and Dr. Alexander Sherwood (medicinal chemist). Usona's psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study (the largest Phase 2 randomised controlled trial of psilocybin for MDD at the time), the Institute launched the Phase 3 uAspire trial in 2024 — a 240-participant, randomised, double-blind, multicentre study comparing 25 mg psilocybin vs placebo in adults with MDD. Usona is also exploring 5-MeO-DMT in early-stage research.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Federal University of Rio Grande do Norte (UFRN)
Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.
Shalvata Mental Health Center
Shalvata Mental Health Center is a 114-bed comprehensive psychiatric hospital founded in 1956 in Hod HaSharon, Israel, affiliated with Clalit Health Services and the Sackler Faculty of Medicine at Tel Aviv University; it is one of Israel's most active psychedelic research sites, having conducted trials comparing intranasal versus intravenous ketamine administration, MDMA-assisted psychotherapy for borderline personality disorder, and ketamine combined with cognitive behavioral analysis system of psychotherapy (CBASP) for chronic treatment-resistant depression.
University Hospital, Bonn
University hospital affiliated with the University of Bonn and one of Europe's leading academic medical centers. Its psychiatry and neuroscience departments have contributed to research on psychedelic-assisted therapies and novel treatments for mood and anxiety disorders.
People
Search →Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
Marta Valle
PhD; researcher/lecturer in Pharmacology, Therapeutics and Toxicology at Universitat Autònoma de Barcelona and associated researcher at Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
She is a key clinical psychopharmacology researcher on human ayahuasca studies, including neurophysiology, pharmacokinetics, and potential therapeutic effects on mindfulness and emotion regulation.
Juan Carlos Pascual
Psychiatrist and researcher at Hospital de la Santa Creu i Sant Pau / Universitat Autònoma de Barcelona
He is a notable clinical psychiatry researcher on ayahuasca, with published work on its effects on mindfulness, emotion regulation, self-compassion, and related therapeutic potential.
Elisabet Domínguez-Clavé
Psychologist, PhD in Pharmacology; clinician and researcher at Hospital de la Santa Creu i Sant Pau (Barcelona)
A leading Spanish ayahuasca and psychedelic researcher whose work has helped characterize post-acute, emotional-regulation, and mindfulness-related effects of ayahuasca.
Brandon Weiss
Assistant Professor of Psychiatry and Behavioral Sciences
Noted for empirical work on personality change and contextual moderators in psychedelic-assisted interventions and for contributions to safety and phenomenology research across ayahuasca and psilocybin studies.
Stephen Ross
Professor of Psychiatry
A leading clinical investigator who has advanced the application of psilocybin-assisted psychotherapy for cancer-related existential distress and substance use disorders through influential clinical trials and qualitative studies.
Rodrigo Mansur
Clinical Researcher in Affective Disorders
Notable for clinical research into psychedelic-assisted psychotherapy and rapid-acting antidepressant treatments for treatment-resistant mood disorders, with emphasis on translational and real-world effectiveness studies.
Robin Carhart-Harris
Ralph Metzner Distinguished Professor
Pioneering researcher in brain imaging of psychedelics and founding director of the UCSF Neuroscape Psychedelics Division.
David Erritzoe
Clinical Associate Professor in Psychopharmacology
Head of the Centre for Psychedelic Research at Imperial College London and director of the CIPPRes Clinic.
Fernanda Palhano-Fontes
Research Engineer at the Brain Institute, UFRN
Led the world's first double-blind, placebo-controlled trial of ayahuasca for treatment-resistant depression.
Connected Evidence
The latest clinical data and verified academic findings associated with Personality Disorders.